RESTASIS .5 mg/mL (Cyclosporine EMULSION) .5 mg/mL

RESTASIS .5 mg/mL is an ophthalmic emulsion containing cyclosporine, designed to help manage chronic dry eye symptoms. This single-use treatment is formulated to support eye health and comfort.

Strength

.5 mg/mL

Pack Size

30 VIAL, SINGLE-USE in 1 TRAY (0023-9163-30) / .4 mL in 1 VIAL, SINGLE-USE

Manufacturer / TM Owner

Allergan, Inc.

Select Quantity

Pack/s

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

First Name

Last Name

Phone

Delivery Country

Delivery PostCode/Zipcode

Select Your Profile

I have read and agree to the terms & conditions, including the privacy policy, return policy, and usage terms as applicable to this request.

Indications & Clinical Uses

RESTASIS .5 mg/mL is primarily used to increase tear production in individuals with chronic dry eye disease. This cyclosporine-based emulsion is applied topically to the eyes, aiming to alleviate discomfort associated with insufficient tear production. It is often recommended for those experiencing persistent dryness and irritation.

Side Effects

When used as directed, RESTASIS .5 mg/mL may help reduce symptoms of dry eye, such as redness, irritation, and a gritty feeling. Some users may experience temporary burning or stinging upon application, which typically subsides quickly.

Precautions & Warnings

RESTASIS .5 mg/mL should be handled with care, ensuring the single-use vials are not contaminated. Avoid touching the tip of the vial to prevent infection. Store at room temperature and discard any unused portion after opening.

Avoid Interactions

RESTASIS .5 mg/mL may interact with other eye medications. It is advisable to consult a healthcare provider before using this emulsion alongside other ophthalmic treatments. Additionally, avoid using contact lenses while applying this medication.

Frequently Asked Questions

RESTASIS .5 mg/mL is used to increase tear production in individuals with chronic dry eye disease, helping to alleviate symptoms like dryness and irritation.

RESTASIS .5 mg/mL is applied topically to the eyes using the single-use vials. Ensure the tip of the vial does not touch the eye or any surface to avoid contamination.

Common side effects may include temporary burning or stinging upon application, which usually subsides quickly.

It is advisable to consult a healthcare provider before using RESTASIS .5 mg/mL with other eye medications to avoid potential interactions.

RESTASIS .5 mg/mL should be stored at room temperature and discarded after opening to maintain its effectiveness.

Editorial & Trust Signals

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical wholesaler & exporter

Last updated: 17 Jun 2026

References

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.